Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Colorcon
Dow
McKesson
Harvard Business School
Mallinckrodt

Last Updated: May 28, 2022

CLINICAL TRIALS PROFILE FOR OFLOXACIN


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Ofloxacin

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00002249 ↗ A Double-Blind Study to Evaluate the Safety and Pharmacokinetics of L-Ofloxacin (RWJ 25213) in Subjects With HIV Infection Completed R W Johnson Pharmaceutical Research Institute Phase 1 1969-12-31 To determine the safety and pharmacokinetics of L-ofloxacin (RWJ 25213) in patients with HIV infection.
NCT00002850 ↗ Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy Completed Eastern Cooperative Oncology Group Phase 3 1997-03-01 RATIONALE: Giving antibiotics may be effective in preventing or controlling early infection in patients with multiple myeloma and may improve their response to chemotherapy. PURPOSE: This randomized clinical trial is studying antibiotics to see how well they work compared to no antibiotics in preventing early infection in patients with multiple myeloma.
NCT00002850 ↗ Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy Completed National Cancer Institute (NCI) Phase 3 1997-03-01 RATIONALE: Giving antibiotics may be effective in preventing or controlling early infection in patients with multiple myeloma and may improve their response to chemotherapy. PURPOSE: This randomized clinical trial is studying antibiotics to see how well they work compared to no antibiotics in preventing early infection in patients with multiple myeloma.
NCT00002850 ↗ Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy Completed Gary Morrow Phase 3 1997-03-01 RATIONALE: Giving antibiotics may be effective in preventing or controlling early infection in patients with multiple myeloma and may improve their response to chemotherapy. PURPOSE: This randomized clinical trial is studying antibiotics to see how well they work compared to no antibiotics in preventing early infection in patients with multiple myeloma.
NCT00042289 ↗ Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy Completed Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) 2003-03-01 The purpose of this study is to evaluate the pharmacokinetics (PKs) of antiretroviral (ARV) and tuberculosis (TB) medications in pregnant women and their infants. (Pharmacokinetics are the various interactions between a drug and the body.) This study will also evaluate the PKs of certain ARVs in postpartum women before and after starting hormonal contraceptives. The PKs of these drugs will be evaluated by measuring the amount of medicine present in blood and/or vaginal secretions.
NCT00042289 ↗ Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy Completed National Institute of Allergy and Infectious Diseases (NIAID) 2003-03-01 The purpose of this study is to evaluate the pharmacokinetics (PKs) of antiretroviral (ARV) and tuberculosis (TB) medications in pregnant women and their infants. (Pharmacokinetics are the various interactions between a drug and the body.) This study will also evaluate the PKs of certain ARVs in postpartum women before and after starting hormonal contraceptives. The PKs of these drugs will be evaluated by measuring the amount of medicine present in blood and/or vaginal secretions.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Ofloxacin

Condition Name

Condition Name for Ofloxacin
Intervention Trials
Pelvic Inflammatory Disease 3
HIV Infections 2
Infection 2
Ofloxacin 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Ofloxacin
Intervention Trials
Infection 5
Infections 5
Communicable Diseases 4
Pelvic Inflammatory Disease 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Ofloxacin

Trials by Country

Trials by Country for Ofloxacin
Location Trials
United States 48
South Africa 7
United Kingdom 6
Thailand 5
Germany 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Ofloxacin
Location Trials
Washington 4
New York 4
New Jersey 3
Missouri 2
Alabama 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Ofloxacin

Clinical Trial Phase

Clinical Trial Phase for Ofloxacin
Clinical Trial Phase Trials
Phase 4 12
Phase 3 10
Phase 2 3
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Ofloxacin
Clinical Trial Phase Trials
Completed 19
Unknown status 7
Terminated 2
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Ofloxacin

Sponsor Name

Sponsor Name for Ofloxacin
Sponsor Trials
Genaera Corporation 2
Montefiore Medical Center 2
Abeona Therapeutics, Inc 2
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Ofloxacin
Sponsor Trials
Other 41
Industry 9
NIH 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Baxter
McKesson
Moodys
Mallinckrodt
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.